Imagine taking a medicine that prevents strokes by making your blood slippery, but then you get a cut that won't stop bleeding. Right now, there isn't a reliable 'off switch' for the newest type of these drugs. This project created a biological key that quickly restarts the clotting process to save lives in emergencies.
Patients using FXa-DOACs lack a safe reversal agent to stop life-threatening bleeding, leading to over 400,000 hospital admissions annually.
VMX-C001, a recombinant protein bypass agent, and an optimized CHO-based manufacturing process to reduce production costs.
If you are a drug manufacturer dealing with the safety gaps of FXa-DOACs — this project developed VMX-C001 that acts as a safe reversal agent. It addresses a critical need for the 10 million patients in the EU and US using these medications.
If you are a hospital operator dealing with over 400,000 annual admissions for bleeding complications — this project developed a bypass agent that reduces morbidity and mortality. This could significantly lower the burden on critical care units.
If you are a CDMO dealing with complex recombinant protein production — this project developed an optimized CHO cell line process for VMX-C001. It focuses on lowering the Cost of Goods Sold (COGS) for high-yield biologics.
The project specifically focused on process optimization to lower the Cost of Goods Sold (COGS) by refining the manufacturing process of the CHO-based cell line.
VarmX is currently working to accelerate upscaling and improve cost-effectiveness, although recent attempts to create new cell lines for a 2- to 4-fold efficiency increase did not meet benchmarks.
Based on available project data, VarmX BV owns the development of VMX-C001, but specific licensing terms are not disclosed.
The product targets the over 10 million patients in the EU and US using Factor Xa Direct Oral Anticoagulants (FXa-DOACs).
The project period runs from 2022-09-01 to 2025-03-31.
The project is led by a single SME, VarmX BV from the Netherlands, representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, supported by a total financial package of €17.5 million (grant and equity), and the use of external CROs and academic labs for technical execution rather than a formal consortium.
Contact VarmX BV in the Netherlands
Request detailed manufacturing optimization data for VMX-C001
